Smitha Rudraraju, M.D. Internal Medicine - Rheumatology Medicare: Medicare Enrolled Practice Location: 4716 Alliance Blvd Ste 775, Plano, TX 75093 Phone: 469-800-6000 Fax: 469-800-6000 |
Dr. Bal Krishna Khandelwal, M.D. Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: Primary Care Clinic Of North Texas (charity Clinic), 3900 American Drive, #201, Plano, TX 75075 Phone: 972-596-6005 Fax: 972-596-6004 |
Varuni Rao, D.O. Internal Medicine - Rheumatology Medicare: Medicare Enrolled Practice Location: 6201 Dallas Pkwy # 100, Plano, TX 75024 Phone: 972-403-8184 Fax: 972-403-0685 |
Dr. Su Yin, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 4708 Alliance Blvd, Suite 310, Dallas Diagnostic Association, Plano, TX 75093 Phone: 972-758-6000 |
Zainab Shahnawaz, Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 6513 Preston Rd Ste 300, Plano, TX 75024 Phone: 214-216-6564 Fax: 214-385-2574 |
Fang Wang, D.O. Internal Medicine - Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 4625 Meadow Ridge Dr, Plano, TX 75093 Phone: 214-663-4029 Fax: 972-669-1313 |
Fehmida Zahabi, MD Internal Medicine - Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 6300 Stonewood Dr, Suite 412, Plano, TX 75024 Phone: 469-467-2478 Fax: 469-467-8146 |
News Archive
Runners who wear trainers with no cushioning and land on the ball of their foot rather than the heel put significantly less demand on their bodies, new research suggests.
Professor Ron Grunstein, Head of the Sleep and Circadian Research Group and Dr Naomi Rogers, chronobiologist both of the Woolcock Institute of Medical Research, have questioned the ability of doctors in Australia's hospitals to do their job properly given the long hours many are expected to work.
Senesco Technologies, Inc. today announced that the Company has filed an Investigational New Drug application with the U.S. Food and Drug Administration for Senesco's lead drug candidate SNS01-T for treatment of multiple myeloma.
Pfenex Inc. today announced that the Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) has awarded Pfenex a contract providing for up to a total of $18.8 million in funding, provided that certain milestones are achieved and that all contract options and extensions are exercised by the government. The contract will support the development of a robust Pfenex Expression Technology based production strain and process for the production of bulk recombinant protective antigen (rPA) from anthrax.
› Verified 1 days ago